Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Pharmaceuticals Inc (NQ: XERS )

3.080 -0.010 (-0.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO. 
Via Benzinga
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday. 
Via Benzinga
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
Via Benzinga
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
XERS Stock Pops on Huge FDA News. Here’s What to Know.
The FDA approved Xeris' Recorlev drug for certain adult patients with Cushing's syndrome, sending XERS stock higher. 
Via InvestorPlace
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
From Xeris Biopharma Holdings, Inc.
Via Business Wire
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Xeris Biopharma Holdings: Q1 Earnings Insights
Xeris Biopharma Holdings (NASDAQ:XERS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Pharmaceuticals's Earnings Outlook
Xeris Pharmaceuticals (NASDAQ:XERS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
Analyst Ratings For Xeris Biopharma Holdings
Xeris Biopharma Holdings (NASDAQ:XERS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Recap: Xeris Biopharma Holdings Q4 Earnings
Xeris Biopharma Holdings (NASDAQ:XERS) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the... 
Via Benzinga
A Preview Of Xeris Pharmaceuticals's Earnings
Xeris Pharmaceuticals (NASDAQ:XERS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.... 
Via Benzinga
Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
From Xeris Biopharma Holdings
Via Business Wire
Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
From Xeris Biopharma Holdings, Inc.
Via Business Wire
18 Stocks Moving in Monday's Pre-Market Session
Gainers FGI Industries Ltd. (NASDAQ: FGI) rose 92.8% to $7.27 in pre-market trading after jumping 19% on Friday. The company, last week, priced its IPO at $6 per... 
Via Benzinga
Xeris Biopharma Eyes High End Of FY21 Sales Outlook
Xeris Biopharma Holdings Inc (NASDAQ: XERS) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately... 
Via Benzinga
Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update
From Xeris Biopharma Holdings, Inc.
Via Business Wire
PANTHERx Rare Selected By Xeris Pharmaceuticals To Distribute Recorlev
PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy... 
Via Benzinga
Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
From Xeris Biopharma
Via Business Wire
Xeris Biopharma Enters Into Agreement for $30 Million Private Placement
From Xeris Biopharma Holdings, Inc.
Via Business Wire
40 Biggest Movers From Friday
Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its... 
Via Benzinga
The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week. 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
Mid-Afternoon Market Update: Dow Rises 50 Points; Nutriband Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.14% to 36,449.17 while the NASDAQ fell 0.20% to 15,710.56. The S&P also rose, gaining 0.08% to 4,782.32. The U.S. has the... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Xeris Biopharma Holdings
Analysts have provided the following ratings for Xeris Biopharma Holdings (NASDAQ: 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 1%; Xeris Biopharma Shares Jump
Midway through trading Friday, the Dow traded down 0.08% to 36,370.19 while the NASDAQ fell 0.07% to 15,730.21. The S&P also fell, dropping 0.02% to 4,777.65. The U.S. has the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.